Released Jan 29, 2026, after the close
10-K filed Jan 29, 2026, 90 days after period end · 0001654954-26-000710
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.15M$2.15M derived−7.9% vs Q4 2024+9.5% vs Q3 2025
Net Income-$102.00-$102.00 derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$748,935+3.1%
Operating Incomederived-$133,272N/M
Operating Cash Flowderived$279,666+256.6%
Free Cash Flowderived$279,316N/M
Margins · derived
Gross margin34.8%+3.7 pt vs Q4 2024
Operating margin-6.2%+0.4 pt vs Q4 2024
Net margin-0.0%−0.7 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.15M | $2.33M | $3.60M | $4.64M |
| Net Income | -$102.00 | $16.11K | -$47.15K | $173.38K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR